Development of adjuvant treatment of gastric cancer
10.3969/j.issn.1000-8179.2013.15.001
- VernacularTitle:胃癌辅助治疗现状和进展
- Author:
Yi BA
- Publication Type:Journal Article
- Keywords:
gastric cancer;
adjuvant;
neoadjuvant;
chemotherapy;
concurrent radiochemotherapy
- From:
Chinese Journal of Clinical Oncology
2013;(15):879-882
- CountryChina
- Language:Chinese
-
Abstract:
Multidisplinary treatment is the mordent means of local-regional gastric cancer therapy, and individualized treatment decisions are dependent on the patient's characteristics. Stage II patients previously treated with standard D2 resection should receive oral administration of S-1 or combination chemotherapy of XELOX. However, patients at stage IIIb or at a more advanced stage should receive combination treatment as priority. Concurrent radiochemotherapy was recommended to treat patients that had been operated by D0 or D1 resection. Perioperative chemotherapy is more reasonable than pure neoadjuvant chemotherapy. No evidence has verified that perioperative or neoadjuvant chemotherapy leads to better survival compared with postoperative adjuvant chemotherapy. The value of chemotherapy before operation is rest with the effect of downstaging and conversion of the unresectable tumor to a resectable one. Con-current radiochemotherapy prior to an operation needs further investigation to affirm its high efficacy of downstaging and conversion.
